Entering text into the input field will update the search result below

Vir-Alnylam's COVID-19 Therapy, And Other News: The Good, Bad And Ugly Of Biopharma


  • Vir and Alnylam continue progress with their gene silencing therapy for COVID-19.
  • BioMarin progresses with its own gene therapies for various cardiomyopathies.
  • Teva launches Rituxan biosimilar.
  • Looking for more stock ideas like this one? Get them exclusively at The Total Pharma Tracker. Get started today »

Vir and Alnylam Go Ahead with COVID-19 Gene Silencing Therapy

Vir Biotechnology (NASDAQ:VIR) announced a new COVID-19 drug candidate, VIR-2703. The company is collaborating with Alnylam Pharmaceuticals (ALNY) for developing this treatment which is an inhalable RNAi therapeutic which works by targeting the SARS-CoV-2 genome for potentially treating and/or preventing the respiratory illness. Both companies are now planning to meet with the FDA for a probable accelerate pathway for progressing to clinical trials stage.

The collaboration also seeks to identify up to three additional drug candidates for treating COVID-19 as well as other coronavirus ailments. Vir recently received infusion of $250 million from GlaxoSmithKline Plc (GSK). In March this year, Alnylam synthesized 350 siRNAs targeting the SARS-CoV-2 genome. Alnylam Pharmaceuticals CEO John Maraganore said, "To our knowledge, this is one of the most potent direct-acting antivirals targeting SARS-CoV-2 reported to date. As this pandemic continues to unfold, we are committed to acting with the utmost urgency to broaden and accelerate our efforts to develop investigational RNAi therapeutics against COVID-19, and potentially future coronavirus-mediated diseases." The companies are working closely to generate data for facilitating fast commercialization.

VIR-2703 takes a novel approach for treating coronavirus. It employs RNA interference or RNAi technology for silencing particular genetic material leading to the impact on production of proteins responsible for the disease. Alnylam currently has Givlaari and Onpattro, the FDA approved drugs in its portfolio and these drugs are intended to treat rare genetic diseases. The companies plan to file an Investigational New Drug (IND) or IND equivalent application for the drug candidate by the end of this year. The investigational RNAi therapeutic is being developed as an inhalation formula and would be delivered directly to the patient's lungs.

Alnylam is believed to have synthesized more than 350 small interfering RNAs or siRNAs as

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

stephen tips profile picture
Thanks for the article. Interesting information, particularly regarding VIR/ALNY cov-19 research.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About VIR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on VIR

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.